Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka) Unia Europejska - polski - EMA (European Medicines Agency)

lenalidomide krka d.d. novo mesto (previously lenalidomide krka)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - leki immunosupresyjne - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) jest wskazany do leczenia dorosłych pacjentów z wcześniej нелеченной ze szpiczakiem mnogim, którzy nie polega przeszczep. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) jest wskazany do leczenia dorosłych pacjentów z wcześniej нелеченной ze szpiczakiem mnogim, którzy nie polega przeszczep. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto) Unia Europejska - polski - EMA (European Medicines Agency)

lenalidomide krka (previously lenalidomide krka d.d. novo mesto)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - leki immunosupresyjne - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) jest wskazany do leczenia dorosłych pacjentów z wcześniej нелеченной ze szpiczakiem mnogim, którzy nie polega przeszczep. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 i 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) jest wskazany do leczenia dorosłych pacjentów z wcześniej нелеченной ze szpiczakiem mnogim, którzy nie polega przeszczep. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 i 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Prinocate 40 mg / 0,4 ml + 4 mg / 0,4 ml Roztwór do nakrapiania Polska - polski - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

prinocate 40 mg / 0,4 ml + 4 mg / 0,4 ml roztwór do nakrapiania

krka, d.d., novo mesto d.o.o. - imidaclopridum + moxidectinum - roztwór do nakrapiania - 40 mg / 0,4 ml + 4 mg / 0,4 ml - fretka; kot

Prinocate 40 mg / 0,4 ml + 10 mg / 0,4 ml Roztwór do nakrapiania Polska - polski - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

prinocate 40 mg / 0,4 ml + 10 mg / 0,4 ml roztwór do nakrapiania

krka, d.d., novo mesto d.o.o. - imidaclopridum + moxidectinum - roztwór do nakrapiania - 40 mg / 0,4 ml + 10 mg / 0,4 ml - pies

Prinocate 80 mg / 0,8 ml + 8 mg / 0,8 ml Roztwór do nakrapiania Polska - polski - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

prinocate 80 mg / 0,8 ml + 8 mg / 0,8 ml roztwór do nakrapiania

krka, d.d., novo mesto d.o.o. - imidaclopridum + moxidectinum - roztwór do nakrapiania - 80 mg / 0,8 ml + 8 mg / 0,8 ml - kot

Prinocate 100 mg / 1 ml + 25 mg / 1 ml Roztwór do nakrapiania Polska - polski - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

prinocate 100 mg / 1 ml + 25 mg / 1 ml roztwór do nakrapiania

krka, d.d., novo mesto d.o.o. - imidaclopridum + moxidectinum - roztwór do nakrapiania - 100 mg / 1 ml + 25 mg / 1 ml - pies

Prinocate 250 mg / 2,5 ml + 62,5 mg / 2,5 ml Roztwór do nakrapiania Polska - polski - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

prinocate 250 mg / 2,5 ml + 62,5 mg / 2,5 ml roztwór do nakrapiania

krka, d.d., novo mesto d.o.o. - imidaclopridum + moxidectinum - roztwór do nakrapiania - 250 mg / 2,5 ml + 62,5 mg / 2,5 ml - pies

Prinocate 400 mg/4 ml + 100 mg/4 ml Roztwór do nakrapiania Polska - polski - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

prinocate 400 mg/4 ml + 100 mg/4 ml roztwór do nakrapiania

krka, d.d., novo mesto d.o.o. - imidaclopridum + moxidectinum - roztwór do nakrapiania - 400 mg/4 ml + 100 mg/4 ml - pies

Emtricitabine/Tenofovir disoproxil Krka d.d. Unia Europejska - polski - EMA (European Medicines Agency)

emtricitabine/tenofovir disoproxil krka d.d.

krka, d.d., novo mesto - эмтрицитабин, tenofowir disoproxil bursztynian - infekcje hiv - Środki przeciwwirusowe do użytku ogólnoustrojowego - emtrycytabina / dizoproksyl tenofowiru krka d. jest wskazany w skojarzonej terapii przeciwretrowirusowej w leczeniu dorosłych zakażonych hiv-1. emtrycytabina / dizoproksyl tenofowiru krka d. jest również wskazany do leczenia zakażonych hiv-1 nastolatków, z nnrti opór lub toksyczności, wykluczających zastosowanie pierwszego agentów, w wieku od 12 do < 18 lat.

Lenalidomide Krka d.d. Unia Europejska - polski - EMA (European Medicines Agency)

lenalidomide krka d.d.

krka, d.d., novo mesto  - lenalidomide hydrochloride hydrate - multiple myeloma; lymphoma, follicular; myelodysplastic syndromes - leki immunosupresyjne - multiple myelomalenalidomide krka d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) jest wskazany do leczenia dorosłych pacjentów z wcześniej нелеченной ze szpiczakiem mnogim, którzy nie polega przeszczep. lenalidomide krka d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. follicular lymphomalenalidomide krka d. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).